CANF
- Can-Fite BioPharma Ltd.
()
Overview
Company Summary
Can-Fite BioPharma Ltd. (CANF) is a biopharmaceutical company that focuses on the development of innovative drugs to treat various medical conditions. The company primarily specializes in developing drugs that target the immune system and inflammatory responses to combat diseases.
CANF utilizes a unique approach to drug development called the "Israeli Scientist Group" platform, which combines advanced computational technology with leading Israeli scientists' expertise. This platform allows the company to identify specific proteins and molecular pathways involved in diseases, leading to the development of targeted drugs.
The company's drug pipeline includes both original drug candidates and repurposed drugs, which are existing drugs that can be used to treat different diseases than their originally intended ones. CANF's drug candidates target a range of conditions such as cancer, liver disease, inflammatory diseases including rheumatoid arthritis and Crohn's disease, and ophthalmic diseases like glaucoma and dry eye syndrome.
One of the company's lead drugs is Piclidenoson (CF101), an orally bioavailable small molecule that targets A3 adenosine receptors. Piclidenoson is currently in advanced stages of clinical trials for the treatment of several conditions, including rheumatoid arthritis, psoriasis, and liver cancer. Another promising drug is Namodenoson (CF102), which is being developed for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
In addition to drug development, CANF also actively engages in strategic collaborations with pharmaceutical companies, research institutions, and medical centers to facilitate the advancement of their drug candidates. These partnerships help to support and accelerate the clinical development and commercialization of their therapies.
Overall, Can-Fite BioPharma Ltd. is dedicated to developing novel and targeted drugs to address unmet medical needs in various disease areas, with a focus on improving patient outcomes and quality of life.